ABOUT US
MC2 Therapeutics is a private pharmaceutical company dedicated to improving the lives of people with plaque psoriasis and inflamed dry and itchy skin through innovative and effective therapies and support. Read more about MC2 Therapeutics.
Platform
We apply our expertise in formulation and clinical practice to ensure treatment satisfaction for the patients and release of the full clinical potential of therapies.
When topical dosage form is considered the right dosage form, our PAD TechnologyTM formulation and drug delivery system offer several unique advantages in the development of potent innovative new topical therapies for immune-mediated and inflammatory conditions. Read more about our platform.
Pipeline
With a holistic focus on patient care, we have developed dermatological skincare products specifically designed to complement medical treatments and provide soothing relief for dry, itchy skin caused by inflammation. Read more about our pipeline.
LATEST NEWS
MC2 Therapeutics Announces Approval of Wynzora® Cream in Canada
MC2 Therapeutics Announces Approval of Wynzora® Cream in Canada
Copenhagen, December 18, 2026 – MC2 Therapeutics, a ...
MC2 Therapeutics Appoints Trine Ahlgreen as New CEO
Copenhagen, May 27th, 2025 – MC2 Therapeutics, a commercial-stage pharmaceutical company focused on topical therapies in ...
MC2 Therapeutics Announces License and Commercialization Agreement for Wynzora® Cream in Canada
Copenhagen, November 14, 2024 – MC2 Therapeutics, a commercial stage biotech company focused on developing ...
MC2 Therapeutics Receives Positive Feedback from FDA pre-IND Meeting and Updates on Indication Expansion Strategy
- On track to file IND in mid-2025 for a Phase 2b clinical trial in Hidradenitis Suppurativa ...